593 related articles for article (PubMed ID: 12944908)
1. Functional localization and competition between the androgen receptor and T-cell factor for nuclear beta-catenin: a means for inhibition of the Tcf signaling axis.
Mulholland DJ; Read JT; Rennie PS; Cox ME; Nelson CC
Oncogene; 2003 Aug; 22(36):5602-13. PubMed ID: 12944908
[TBL] [Abstract][Full Text] [Related]
2. Ligand-dependent inhibition of beta-catenin/TCF signaling by androgen receptor.
Chesire DR; Isaacs WB
Oncogene; 2002 Dec; 21(55):8453-69. PubMed ID: 12466965
[TBL] [Abstract][Full Text] [Related]
3. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
[TBL] [Abstract][Full Text] [Related]
4. Cross-talk between Rac1 GTPase and dysregulated Wnt signaling pathway leads to cellular redistribution of beta-catenin and TCF/LEF-mediated transcriptional activation.
Esufali S; Bapat B
Oncogene; 2004 Oct; 23(50):8260-71. PubMed ID: 15377999
[TBL] [Abstract][Full Text] [Related]
5. Quercetin, a potent inhibitor against beta-catenin/Tcf signaling in SW480 colon cancer cells.
Park CH; Chang JY; Hahm ER; Park S; Kim HK; Yang CH
Biochem Biophys Res Commun; 2005 Mar; 328(1):227-34. PubMed ID: 15670774
[TBL] [Abstract][Full Text] [Related]
6. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
Murthy S; Agoulnik IU; Weigel NL
Prostate; 2005 Sep; 64(4):362-72. PubMed ID: 15754350
[TBL] [Abstract][Full Text] [Related]
7. TGF-beta signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells.
Zhu ML; Partin JV; Bruckheimer EM; Strup SE; Kyprianou N
Prostate; 2008 Feb; 68(3):287-95. PubMed ID: 18163430
[TBL] [Abstract][Full Text] [Related]
8. Rare activation of the TCF/beta-catenin pathway in ovarian cancer.
Furlong MT; Morin PJ
Gynecol Oncol; 2000 Apr; 77(1):97-104. PubMed ID: 10739697
[TBL] [Abstract][Full Text] [Related]
9. Beta-catenin-related anomalies in apoptosis-resistant and hormone-refractory prostate cancer cells.
de la Taille A; Rubin MA; Chen MW; Vacherot F; de Medina SG; Burchardt M; Buttyan R; Chopin D
Clin Cancer Res; 2003 May; 9(5):1801-7. PubMed ID: 12738737
[TBL] [Abstract][Full Text] [Related]
10. Analysis of Wnt gene expression in prostate cancer: mutual inhibition by WNT11 and the androgen receptor.
Zhu H; Mazor M; Kawano Y; Walker MM; Leung HY; Armstrong K; Waxman J; Kypta RM
Cancer Res; 2004 Nov; 64(21):7918-26. PubMed ID: 15520198
[TBL] [Abstract][Full Text] [Related]
11. 5alpha-androstane-3alpha,17beta-diol supports human prostate cancer cell survival and proliferation through androgen receptor-independent signaling pathways: implication of androgen-independent prostate cancer progression.
Yang Q; Titus MA; Fung KM; Lin HK
J Cell Biochem; 2008 Aug; 104(5):1612-24. PubMed ID: 18320593
[TBL] [Abstract][Full Text] [Related]
12. Interaction and functional cooperation between the LIM protein FHL2, CBP/p300, and beta-catenin.
Labalette C; Renard CA; Neuveut C; Buendia MA; Wei Y
Mol Cell Biol; 2004 Dec; 24(24):10689-702. PubMed ID: 15572674
[TBL] [Abstract][Full Text] [Related]
13. Synergistic activation of the androgen receptor by bombesin and low-dose androgen.
Dai J; Shen R; Sumitomo M; Stahl R; Navarro D; Gershengorn MC; Nanus DM
Clin Cancer Res; 2002 Jul; 8(7):2399-405. PubMed ID: 12114445
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of MAPK-signaling pathway promotes the interaction of the corepressor SMRT with the human androgen receptor and mediates repression of prostate cancer cell growth in the presence of antiandrogens.
Eisold M; Asim M; Eskelinen H; Linke T; Baniahmad A
J Mol Endocrinol; 2009 May; 42(5):429-35. PubMed ID: 19223455
[TBL] [Abstract][Full Text] [Related]
15. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor.
Culig Z; Hobisch A; Cronauer MV; Radmayr C; Trapman J; Hittmair A; Bartsch G; Klocker H
Cancer Res; 1994 Oct; 54(20):5474-8. PubMed ID: 7522959
[TBL] [Abstract][Full Text] [Related]
16. Transcriptional regulation of the androgen signaling pathway by the Wilms' tumor suppressor gene WT1.
Zaia A; Fraizer GC; Piantanelli L; Saunders GF
Anticancer Res; 2001; 21(1A):1-10. PubMed ID: 11299720
[TBL] [Abstract][Full Text] [Related]
17. Isolation of a novel human gene, APCDD1, as a direct target of the beta-Catenin/T-cell factor 4 complex with probable involvement in colorectal carcinogenesis.
Takahashi M; Fujita M; Furukawa Y; Hamamoto R; Shimokawa T; Miwa N; Ogawa M; Nakamura Y
Cancer Res; 2002 Oct; 62(20):5651-6. PubMed ID: 12384519
[TBL] [Abstract][Full Text] [Related]
18. Androgen receptor-mediated repression of novel target genes.
Prescott J; Jariwala U; Jia L; Cogan JP; Barski A; Pregizer S; Shen HC; Arasheben A; Neilson JJ; Frenkel B; Coetzee GA
Prostate; 2007 Sep; 67(13):1371-83. PubMed ID: 17624924
[TBL] [Abstract][Full Text] [Related]
19. Androgen receptor and TGFbeta1/Smad signaling are mutually inhibitory in prostate cancer.
van der Poel HG
Eur Urol; 2005 Dec; 48(6):1051-8. PubMed ID: 16257107
[TBL] [Abstract][Full Text] [Related]
20. Ligand-independent activation of the androgen receptor by the differentiation agent butyrate in human prostate cancer cells.
Sadar MD; Gleave ME
Cancer Res; 2000 Oct; 60(20):5825-31. PubMed ID: 11059779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
